The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in <i>in-vitro</i> fertilization cycles

Marca, Antonio La; Tolani, Aarti Deenadayal; Capuzzo, Martina

doi:10.1080/09513590.2020.1810659

Cited by 7 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of an international standard for AMH tests continues to hinder comparison between studies ( Iliodromiti et al , 2017 ; Magnusson et al , 2017 ; American College of Obstetricians and Gynecologists, 2019 ). However, recent automated assays are beginning to show concordance for gonadotrophin prescribing ( La Marca et al , 2021 ), suggesting that the previously reported differences ( Iliodromiti et al , 2017 ) may now be attenuated and have minimal clinical significance. Some of the studies in our review have analysed small numbers of patients and many were of convenience samples from fertility clinics or otherwise enriched for target populations, potentially leading to outcomes which may not be applicable to the broader population.…”

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Nelson

Davis

Kalantaridou

et al. 2023

Human Reproduction Update

View full text Add to dashboard Cite

BACKGROUND The early onset of menopause is associated with increased risks of cardiovascular disease and osteoporosis. As a woman’s circulating anti-Müllerian hormone (AMH) concentration reflects the number of follicles remaining in the ovary and declines towards the menopause, serum AMH may be of value in the early diagnosis and prediction of age at menopause. OBJECTIVE AND RATIONALE This systematic review was undertaken to determine whether there is evidence to support the use of AMH alone, or in conjunction with other markers, to diagnose menopause, to predict menopause, or to predict and/or diagnose premature ovarian insufficiency (POI). SEARCH METHODS A systematic literature search for publications reporting on AMH in relation to menopause or POI was conducted in PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials up to 31 May 2022. Data were extracted and synthesized using the Synthesis Without Meta-analysis for diagnosis of menopause, prediction of menopause, prediction of menopause with a single/repeat measurement of AMH, validation of prediction models, short-term prediction in perimenopausal women, and diagnosis and prediction of POI. Risk-of-bias was evaluated using the Tool to Assess Risk of Bias in Cohort Studies protocol and studies at high risk of bias were excluded. OUTCOMES A total of 3207 studies were identified, and 41, including 28 858 women, were deemed relevant and included. Of the three studies that assessed AMH for the diagnosis of menopause, one showed that undetectable AMH had equivalent diagnostic accuracy to elevated FSH (>22.3 mIU/ml). No study assessed whether AMH could be used to shorten the 12 months of amenorrhoea required for a formal diagnosis of menopause. Studies assessing AMH with the onset of menopause (27 publications [n = 23 835 women]) generally indicated that lower age-specific AMH concentrations are associated with an earlier age at menopause. However, AMH alone could not be used to predict age at menopause with precision (with estimates and CIs ranging from 2 to 12 years for women aged <40 years). The predictive value of AMH increased with age, as the interval of prediction (time to menopause) shortened. There was evidence that undetectable, or extremely low AMH, may aid early diagnosis of POI in young women with a family history of POI, and women presenting with primary or secondary amenorrhoea (11 studies [n = 4537]). WIDER IMPLICATIONS The findings of this systematic review support the use of serum AMH to study the age of menopause in population studies. The increased sensitivity of current AMH assays provides improved accuracy for the prediction of imminent menopause, but diagnostic use for individual patients has not been rigorously examined. Prediction of age at menopause remains imprecise when it is not imminent, although the finding of very low AMH values in young women is both of clinical value in indicating an increased risk of developing POI and may facilitate timely diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Nelson

Davis

Kalantaridou

et al. 2023

Human Reproduction Update

View full text Add to dashboard Cite

show abstract

“…In previous studies, the Access-AMH levels and Elecsys-AMH levels in the same patient showed a significant correlation, and there was a tendency for higher levels to be measured using Access-AMH than using Elecsys-AMH [14,20,21]. In the present study, we evaluated the association of oocyte number with Access-AMH levels or Elecsys-AMH levels in different cohorts of patients undergoing stimulated IVF cycles, and determined the cut-off of Access-AMH or Elecsys-AMH to predict poor responders (3 or fewer oocytes) or high responders (15 or more oocytes).…”

Section: Introductionmentioning

confidence: 84%

“…La Marca et al [20] reported that the Access-AMH level was usually higher than the Elecsys-AMH level. When calculating the dose of follitropin alfa, Access-AMH value was used instead of the Elecsys-AMH value, and a ≥ 15% difference in the starting dose occurred in only 2 of 113 patients.…”

Section: Table 3 the Equations Between Serum Amh Level And Four Stimu...mentioning

confidence: 98%

Correlation of oocyte number with serum anti-Müllerian hormone levels measured by either Access or Elecsys in fresh in vitro fertilization cycles

Jeong¹,

Kim²,

Lee³

et al. 2022

Clin Exp Reprod Med

View full text Add to dashboard Cite

Objective: The aim of this study was to assess the correlation of oocyte number with serum anti-Müllerian hormone (AMH) levels measured by two automated methods (Access or Elecsys) in fresh stimulated in vitro fertilization (IVF) cycles.Methods: In this retrospective study at a university hospital, data were collected from 243 fresh stimulated IVF cycles performed from August 2016 to December 2020. The serum AMH level was measured by Access in 120 cycles and by Elecsys in 123 cycles. The cut-off of serum AMH for prediction of poor responders (three or fewer oocytes) or high responders (15 or more oocytes) was calculated by the receiver operating characteristic curve analysis.Results: For the two automated methods, the following equations were derived: total oocyte number=2.378+1.418×(Access-AMH) (r=0.645, p<0.001) and total oocyte number=2.417+2.163×(Elecsys-AMH) (r=0.686, p<0.001). The following combined equation could be derived: (Access-AMH)=0.028+1.525×(Elecsys-AMH). To predict poor responders, the cut-off of Access-AMH was 1.215 ng/mL (area under the curve [AUC], 0.807; 95% confidence interval [CI], 0.730–0.884; p<0.001), and the cut-off of Elecsys-AMH was 1.095 ng/mL (AUC, 0.848; 95% CI, 0.773–0.923; p<0.001). To predict high responders, the cut-off of Access-AMH was 3.450 ng/mL (AUC, 0.922; 95% CI, 0.862–0.981; p<0.001), and the cut-off of Elecsys-AMH was 2.500 ng/mL (AUC, 0.884; 95% CI, 0.778–0.991; p<0.001).Conclusion: Both automated methods for serum AMH measurement showed a good correlation with oocyte number and good performance for predicting poor and high responders in fresh stimulated IVF cycles. The Access method usually yielded higher measured serum AMH levels than the Elecsys method.

show abstract

“…It is worth noting that previous studies have found that commercial AMH assays may exhibit an intercycle variation exceeding 20% and reach 163% [49][50][51], which was associated with a lack of standardized AMH tests [52][53][54]. This has first limited result comparisons, but this concern was resolved since current assays started to display concordance for gonadotrophin prescribing [55].…”

Section: Nsmentioning

confidence: 99%

The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials

Doroftei,

Ilie,

Dabuleanu

et al. 2024

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To investigate whether the ovarian stimulation with follitropin delta in an individualized algorithm-based manner is inferior to recombinant human-follicle stimulating’s follitropin alfa or follitropin beta conventional dosing regarding a series of established primary endpoints. Methods We conducted a registered systematic review (CRD42024512792) on PubMed-MEDLINE, Web of Science™, Cochrane Database of Systematic Reviews, and Scopus. Our search was designed to cover all relevant literature, particularly randomized controlled trials. We critically and comparatively analyzed the outcomes for each primary endpoint based on the intervention, reflected by the positive βhCG test, clinical pregnancy, vital pregnancy, ongoing pregnancy, live birth, live birth at 4 weeks, and multiple pregnancies. Results Six randomized controlled trials were included in the quality assessment as priority manuscripts, revealing an 83.3% low risk of bias. Follitropin delta led to non-significant differences in each parameter of interest from positive βhCG test (691; 53.44% vs. 602; 46.55%), ongoing pregnancies (603; 53.79% vs. 518; 46.20%), clinical and vital pregnancies (1,073; 52.80% vs. 959; 47.19%), to live birth and at 4 weeks (595; 54.14% vs. 504; 45.85%) with only 2 losses, and even multiple pregnancies (8; 66.66% vs. 4; 33.33%). However, follitropin delta was well-tolerated among hypo- and hyper-responders without significant risk of ovarian hyperstimulation syndrome and/or preventive interventions in contrast with follitropin alfa or follitropin beta. Conclusion The personalized individualized-based algorithm dosing with follitropin delta is non-inferior to conventional follitropin alfa or follitropin beta. It is as effective in promoting a similar response in women without significant comparable adverse effects.

show abstract

The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles

Cited by 7 publications

References 15 publications

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Correlation of oocyte number with serum anti-Müllerian hormone levels measured by either Access or Elecsys in fresh in vitro fertilization cycles

The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials

Contact Info

Product

Resources

About